119 related articles for article (PubMed ID: 26542057)
1. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Nygård SB; Vainer B; Nielsen SL; Bosman F; Tejpar S; Roth A; Delorenzi M; Brünner N; Budinska E
Clin Cancer Res; 2016 Apr; 22(7):1621-31. PubMed ID: 26542057
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
Nygård SB; Christensen IJ; Nielsen SL; Nielsen HJ; Brünner N; Spindler KL
Scand J Gastroenterol; 2014 Jan; 49(1):84-91. PubMed ID: 24256029
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
Palshof JA; Høgdall EV; Poulsen TS; Linnemann D; Jensen BV; Pfeiffer P; Tarpgaard LS; Brünner N; Stenvang J; Yilmaz M; Nielsen DL
BMC Cancer; 2017 Jan; 17(1):48. PubMed ID: 28077117
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
Kümler I; Balslev E; Stenvang J; Brünner N; Nielsen D
BMC Cancer; 2015 Feb; 15():78. PubMed ID: 25885574
[TBL] [Abstract][Full Text] [Related]
6. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
7. Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
Kümler I; Balslev E; Stenvang J; Brünner N; Ejlertsen B; Jakobsen EH; Nielsen DL
BMC Cancer; 2019 Jun; 19(1):573. PubMed ID: 31196001
[TBL] [Abstract][Full Text] [Related]
8. TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas.
Grunnet M; Calatayud D; Schultz NA; Hasselby JP; Mau-Sørensen M; Brünner N; Stenvang J
Scand J Gastroenterol; 2015 Apr; 50(4):485-94. PubMed ID: 25615400
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis.
Rømer MU; Nygård SB; Christensen IJ; Nielsen SL; Nielsen KV; Müller S; Smith DH; Vainer B; Nielsen HJ; Brünner N
Mol Oncol; 2013 Feb; 7(1):101-11. PubMed ID: 23110915
[TBL] [Abstract][Full Text] [Related]
10. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.
Rømer MU; Jensen NF; Nielsen SL; Müller S; Nielsen KV; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2012 Jan; 47(1):68-79. PubMed ID: 22171973
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer.
Kümler I; Balslev E; Poulsen TS; Nielsen SL; Nygård SB; Rømer MU; Christensen IJ; Høgdall E; Moreira J; Nielsen DL; Brünner N; Stenvang J
Int J Cancer; 2015 Oct; 137(8):2000-6. PubMed ID: 25855483
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort.
Smith DH; Christensen IJ; Jensen NF; Markussen B; Rømer MU; Nygård SB; Müller S; Nielsen HJ; Brünner N; Nielsen KV
PLoS One; 2013; 8(4):e60613. PubMed ID: 23577133
[TBL] [Abstract][Full Text] [Related]
13. Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
Buhl IK; Gerster S; Delorenzi M; Jensen T; Jensen PB; Bosman F; Tejpar S; Roth A; Brunner N; Hansen A; Knudsen S
PLoS One; 2016; 11(5):e0155123. PubMed ID: 27171152
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
[TBL] [Abstract][Full Text] [Related]
17. Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan.
Meisenberg C; Gilbert DC; Chalmers A; Haley V; Gollins S; Ward SE; El-Khamisy SF
Mol Cancer Ther; 2015 Feb; 14(2):575-85. PubMed ID: 25522766
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Zhao M; Gjerset RA
PLoS One; 2015; 10(8):e0134929. PubMed ID: 26248194
[TBL] [Abstract][Full Text] [Related]
19. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
Rolle CE; Kanteti R; Surati M; Nandi S; Dhanasingh I; Yala S; Tretiakova M; Arif Q; Hembrough T; Brand TM; Wheeler DL; Husain AN; Vokes EE; Bharti A; Salgia R
Mol Cancer Ther; 2014 Mar; 13(3):576-84. PubMed ID: 24327519
[TBL] [Abstract][Full Text] [Related]
20. Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
McLeod HL; Keith WN
Br J Cancer; 1996 Aug; 74(4):508-12. PubMed ID: 8761363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
